Clinical

Review on the use of hydroxyurea – 50 years of FDA approval

By: Jonathan Mercado, PharmD Candidate c/o 2019 - Hydroxyurea is a versatile, multi-functional drug that has been used for decades…

9 years ago

Safety and efficacy of a new drug: sofosbuvir/velpatasvir/voxilaprevir (Vosevi®)

By: Shireen Farzadeh, PharmD Candidate c/o 2019 - Sofosbuvir/velpatasvir/voxilaprevir (Vosevi®) is the first pangenotypic fixed-dose combination tablet that includes 400…

9 years ago

Pharmacy Pearls: Current Treatment for Hepatitis C

By: Vicky Liu, PharmD Candidate c/o 2018 - Hepatitis is an inflammation of the liver commonly caused by viruses which…

9 years ago

Ketogenic Diets for Diabetes Mellitus and Obesity

By: Anna Chen, PharmD Candidate c/o 2020 - Every day the public faces an onslaught of a new fad diet…

9 years ago

The function and efficacy of pimavanserin (Nuplazid®) in the treatment of psychosis associated with Parkinson’s Disease

By: Jonathan Mercado, PharmD Candidate c/o 2019 - In April 2016, the FDA approved the first drug specifically indicated for…

9 years ago

The Importance of Inhaler Education: A Comprehensive Review

By: Jack (Hongkai) Bao, PharmD Candidate c/o 2018 - Inhalers are one of the most prescribed therapies used to treat…

9 years ago

Evaluating Pharmacy Curriculum Outcomes Assessment and NAPLEX Performance, Phase 1

By: Zachary Piracha, PharmD Candidate c/o 2017 - BACKGROUND The pharmacy profession is constantly fortified by an ever-evolving process by…

9 years ago

Stevens-Johnson Syndrome: Physiological Progression and Management

By: Omar Rahman, PharmD Candidate c/o 2017 - Stevens-Johnson Syndrome is a unique skin disease that may be due to…

9 years ago

The Relationship Between Blueberry Supplementation and Memory Function

By: Amy Nguyen, PharmD Candidate c/o 2020 and Alex Chu, PharmD Candidate c/o 2019 - One of the most common…

9 years ago

Brexpiprazole: A Novel Antipsychotic for Major Depressive Disorder and Schizophrenia

By: Nicollette Pacheco, Staff Editor [Graphics-focused] - Brexpiprazole (REXULTI®) is a novel atypical antipsychotic that was approved in July 2015…

10 years ago